PPAR-γ receptor agonist rosiglitazone was found to inhibit the expression of NF-kB in asthmatic mice, reducing the expression of downstream inflammatory factors IL-4 and IL-13, and further inhibiting the activation of TLR2/NLRP3 inflammasomes, which ultimately inhibited the pyroptosis-related signal transduction pathway and reduced airway inflammation in asthmatic mice (104). Here, NLRP3 is linked to inflammatory response.